Alzheimer’s Disease – From Fundamental Insights to Light at the End of the Translational Tunnel

Alzheimer’s disease (AD), Parkinson’s disease (PD) and related neurodegenerative disorders are becoming increasingly more prevalent in the United States and globally due to the longevity revolution. The consequences of these diseases are grave, both for individuals and the global community, prompting concerns that rising healthcare costs have the potential to result in deleterious effects on national economies that could spell disaster unless disease modifying therapies are discovered very soon. Fortunately, remarkable progress has been made towards elucidating mechanisms of AD since the discovery of the Abeta peptide in 1984 which launched the molecular era of AD research. That, coupled with the demonstration that tau is building block of AD tangles in 1991 led to the understanding that AD, PD and most other neurodegenerative disorders are protein misfolding diseases which has led to further clarity about mechanisms underlying AD, and this has culminated in the identification of new targets for disease modifying therapies as well as biomarkers for AD. Most recently, provocative data have emerged suggesting that the progression of AD may be due to the cell-to-cell spread of pathological species of tau and Abeta, thereby ushering in exciting new opportunities to arrest AD progression with immune therapies. Thus, the purpose of this meeting, which is held in concert with the parallel PD meeting, is to explore these fundamental insights into mechanisms of AD and the opportunities they provide to translate this knowledge into meaningful interventions for AD.
+ show speakers and program
SUNDAY, MARCH 2

16:00—20:00 Arrival and Registration


MONDAY, MARCH 3

07:00—08:00 Breakfast

08:00—09:00 Keynote Address (Joint)
Registered attendees can view abstracts starting on 02/02/2014

Michel Goedert, Medical Research Council, UK
AD and PD Are Protein Misfolding Diseases

09:00—11:15 Phenotypic and Genotypic Complexity of AD and PD (Joint)
Registered attendees can view abstracts starting on 02/02/2014

Andrew B. Singleton, NIA, National Institutes of Health, USA
Genetics of AD and PD

Dennis W. Dickson, Mayo Clinic, USA
Pathological Overlap of AD and PD

Ryan J. Watts, Genentech, Inc., USA
Study of Crenezumab, an Anti-Abeta Antibody, in Early Alzheimer's Disease

Short Talk(s) Chosen from Abstracts

09:40—10:00 Coffee Break

11:15—13:00 Poster Setup

13:00—22:00 Poster Viewing

On Own for Lunch and Recreation

16:00—16:30 Coffee Available

16:30—18:30 Genetics of AD
Registered attendees can view abstracts starting on 02/02/2014

Christine Van Broeckhoven, Neurodegenerative Brain Diseases Group, VIB and University of Antwerp, Belgium
Genetics of Familial AD

Richard Mayeux, Columbia University, USA
Genetics of Late Onset AD

Gerard D. Schellenberg, University of Pennsylvania, USA
New AD Risk Factor Genes from GWAS

Short Talk Chosen from Abstracts


Following Session is for Parkinson’s Disease: Genetics, Mechanisms and Therapeutics (Q7)

16:30—18:30 Genome-Wide Association and PD
Registered attendees can view abstracts starting on 02/02/2014

Thomas Gasser, University of Tübingen, Germany
GWA Studies and PD - New Pathways and Old Targets

Vincent Plagnol, UCL Genetics Institute, UK
Deciphering the Role of LRRK2 in Genome-Wide Susceptibility to PD

Haydeh Payami, Wadsworth Center, New York State Department of Health, USA
Interaction between Genes and Environment in PD

Short Talk Chosen from Abstracts

18:30—19:30 Social Hour w/ Lite Bites

19:30—22:00 Poster Session 1


TUESDAY, MARCH 4

07:00—08:00 Breakfast

08:00—11:00 Biomarkers of AD and PD (Joint)
Registered attendees can view abstracts starting on 02/02/2014

Ronald C. Petersen, Mayo Clinic, USA
Temoporal Ordering of AD Biomarkers Based on ADNI Data

Kenneth L. Marek, Institute for Neurodegenerative Disorders, USA
Parkinson Progression Marker Initiative

Kaj Blennow, University of Gothenburg, Sweden
CSF Biomarkers for AD: Approaching the End of the Long Road to Validated and Approved Biomarkers

Thomas J. Montine, University of Washington Medical Center, USA
CSF and Proteomic Studies of AD and PD Biomarkers

Short Talk(s) Chosen from Abstracts

09:20—09:40 Coffee Break

11:00—13:00 Poster Setup

13:00—22:00 Poster Viewing

On Own for Lunch and Recreation

14:30—16:30 Panel: Combo Therapy for AD

* Rusty Katz†, U.S. Food and Drug Administration, USA

16:00—16:30 Coffee Available

16:30—18:30 AD Biomarkers
Registered attendees can view abstracts starting on 02/02/2014

Daniel M. Skovronsky, Avid Radiopharmaceuticals, Inc., USA
Amyloid Imaging

Clifford R. Jack, Mayo Clinic, USA
MRI of AD

David M. Holtzman, Washington University, USA
CSF Biomarkers and Sleep Biomarkers as Diagnostic and Progostic Factors in Preclinical Alzheimers' Disease

Short Talk Chosen from Abstracts


Following Session is for Parkinson’s Disease: Genetics, Mechanisms and Therapeutics (Q7)

16:30—18:30 Mitochondrial Biology and the Pathology of PD
Registered attendees can view abstracts starting on 02/02/2014

Richard J. Youle, NINDS, National Institutes of Health, USA
Mitophagy and the Etiology of Parkinsonism

Helene Marie Plun-Favreau, University College London Institute of Neurology, UK
Novel Players in Mitochondrial Quality Control and Genetic PD

Alex J. Whitworth, University of Sheffield, UK
Young Onset PD: Lessons from Drosophila

Short Talk Chosen from Abstracts

18:30—19:30 Social Hour w/ Lite Bites

19:30—22:00 Poster Session 2

WEDNESDAY, MARCH 5

07:00—08:00 Breakfast

08:00—11:00 What Are the Toxic Species of Tau, Abeta and alpha-Synuclein (Joint)
Registered attendees can view abstracts starting on 02/02/2014

Karen Hsiao Ashe, University of Minnesota, USA
Toxic Species of Tau and Abeta

Dennis J. Selkoe, Harvard Medical School, USA
Protein Misfolding in Alzheimer's and Parkinson's Disease: New Mechanistic Insights

Susan Lindquist, HHMI/Whitehead Institute for Biomedical Research, USA
Toxic Species of alpha-Synuclein

Hilal A. Lashuel, Swiss Federal Institute of Technology, Switzerland
Toxic Species of alpha-Synuclein

Short Talk(s) Chosen from Abstracts

09:20—09:40 Coffee Break

11:00—13:00 Poster Setup

13:00—22:00 Poster Viewing

On Own for Lunch and Recreation

16:00—16:30 Coffee Available

16:30—18:30 Transmission of Tau and Abeta
Registered attendees can view abstracts starting on 02/02/2014

John Q. Trojanowski, University of Pennsylvania, USA
Transmission of tau Pathology with Synthetic tau Fibrils in tau Tg Mice

Virginia M. Y. Lee, University of Pennsylvania School of Medicine, USA
Transmission of alpha-Synuclein

Karen Duff, Columbia University, USA
Transmission of Tau

Short Talk Chosen from Abstracts


Following Session is for Parkinson’s Disease: Genetics, Mechanisms and Therapeutics (Q7)

16:30—18:30 Pluripotent Stem Cells and Inherited PD
Registered attendees can view abstracts starting on 02/02/2014

Tilo Kunath, University of Edinburgh, UK
alpha-Synuclein Dysfunction in Pluripotent Stem Cell Derived Neuronal Cells

Dimitri Krainc, Massachusetts General Hospital, USA
GBA Mutations and PD

Jared Sterneckert, Max-Planck-Institut für Molekulare Biomedizin, Germany
New Insights into PD Associated with Mutant LRRK2 Using Human iPSCs

Short Talk Chosen from Abstracts

18:30—19:30 Social Hour w/ Lite Bites

19:30—22:00 Poster Session 3

THURSDAY, MARCH 6

07:00—08:00 Breakfast

08:00—11:00 Passive Immunization and Other Novel Therapies to Treat AD and PD (Joint)
Registered attendees can view abstracts starting on 02/02/2014

Eliezer Masliah, University of California, San Diego, USA
Passive Immunization to Treat PD

Kurt R. Brunden, University of Pennsylvania, USA
Microtubule Stabilizing Drugs to Treat Axonal Transport Failure in AD and PD

David S. Bredt, Janssen, USA
Translating Alzheimer’s Disease Science into Breakthrough Therapies

Michael Hutton, Eli Lilly Research Center, UK
Passive Immunization to Treat AD

Short Talk(s) Chosen from Abstracts

09:20—09:40 Coffee Break

On Own for Lunch and Recreation

16:00—16:30 Coffee Available

16:30—18:30 AD Prevention versus Intervention Trials
Registered attendees can view abstracts starting on 02/02/2014

Reisa A. Sperling, Brigham & Women's Hospital, Harvard Medical School, USA
Sporadic AD Prevention Trials

Suzanne Craft, Wake Forest University School of Medicine, USA
Talk Title to be Determined

Mark S. Forman, Merck, USA
BACE Inhibitors for AD Intervention and Prevention

Short Talk Chosen from Abstracts


Following Session is for Parkinson’s Disease: Genetics, Mechanisms and Therapeutics (Q7)

16:30—18:30 LRRK2 Biology and PD Therapeutics
Registered attendees can view abstracts starting on 02/02/2014

Mark Cookson, NIA, National Institutes of Health, USA
State-of-the-Protein on LRKK2 Biology

Alastair D. Reith, GlaxoSmithKline Medicines Research, UK
Industry Viewpoint on Targeting LRRK2

Dario Alessi, University of Dundee, UK
Talk Title to be Determined

Alfred Wittinghofer, Max Planck Institut, Germany
Structural Studies on Roco Proteins and Implications for LRRK2

18:30—19:30 Social Hour w/ Lite Bites

19:30—22:30 Entertainment

FRIDAY, MARCH 7

Departure

2 Mar - 7 Mar 2014
Keystone
United States of America
meeting website